ClinicalTrials.gg
CompletedNCT02782663Updated Aug 13, 2026Results posted

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

A Phase 2 interventional study of ABT-494 in Crohn's Disease (CD), sponsored by AbbVie. Completed at 61 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
20th of 27
107 · median 220
Started
2016
with 2 others
Phase 2
8 of 55
2 open now
Registered
25th of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2016, is one of 8 in phase 2, and was the 25th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

03

Conditions studied

  • Crohn's Disease (CD)

Browse trials for

Keywords

  • Crohn's Disease
  • Efficacy
  • Safety
  • Tolerability
  • ABT-494
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have completed Study M13-740 through Week 52.
  • If female, participant must be , surgically sterile or on using a method.

Exclusion criteria

Exclusion Criteria:

  • For any reason participant is considered by the investigator to be an unsuitable candidate
  • Female participant with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study.
  • Participant is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Upadacitinib (ABT-494) Dose B

    Open label dose B QD

    Drug: ABT-494

  • Experimental
    Upadacitinib (ABT-494) Dose A

    Open label dose A once daily (QD)

    Drug: ABT-494

Interventions

  • Tablet: Oral

    Also known as: Upadacitinib, RINVOQ

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Endoscopic Remission at Month 12

    Endoscopic remission was based on Simplified Endoscopic Score for Crohn's disease (SES-CD). The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.

    Time frame: Month 12

  2. Percentage of Participants Achieving Clinical Remission at Month 12

    Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than Baseline and average daily abdominal pain score ≤1.0 and not worse than baseline in Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

    Time frame: Month 12

Secondary outcomes

  1. Percentage of Participants Achieving Endoscopic Remission

    Endoscopic remission was based on SES-CD. The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

    Time frame: Week 0 (Baseline), Months 24, 36, 48, 60, 72, 84, and 96

  2. Percentage of Participants Achieving Clinical Remission

    Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  3. Percentage of Participants Achieving Modified Clinical Remission

    Modified Clinical Remission was defined as average daily stool frequency ≤2.8 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740, among participants with stool frequency ≥4.0 or abdominal pain score ≥2.0 at Baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  4. Percentage of Participants Achieving Remission

    Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  5. Percentage of Participants Achieving CDAI Remission

    CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a pre-specified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher CDAI scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI remission was defined as CDAI score \<150.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  6. Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission

    The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range: 32 to 224. A higher score indicating better outcome. IBDQ remission was defined as IBDQ score ≥170.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  7. Percentage of Participants Achieving Endoscopic Improvement

    Endoscopic improvement was defined as SES-CD at least 50% reduction from Baseline or endoscopic remission. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  8. Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free at the Specified Timepoint in Study M14-327

    Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96

  9. Percentage of Participants Achieving Remission and Normal C-Reactive Protein (CRP)

    Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated: none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over the past 7 days and multiplied by a prespecified factor of 5; total score range from 0 to 105. Endoscopic remission was based on SES-CD and assessed size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum; scored 0 to 3 per segment. Sum of scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Normal CRP=high-sensitivity CRP \<5 mg/L.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  10. Percentage of Participants in Remission at Week 0 Who Maintained Remission

    Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

    Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96

  11. Percentage of Participants in Endoscopic Remission at Week 0 Who Maintained Endoscopic Remission

    Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

    Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96

  12. Percentage of Participants Achieving Response

    Response = clinical and endoscopic response. Clinical response was average daily stool frequency at least 30% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain based on CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over past 7 days and multiplied by prespecified factor of 5; total score range from 0-105. Endoscopic response was decrease ≥25% SES-CD from baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, rectum), scored 0 to 3 per each segment. Sum of the scores for each endoscopic variable ranged from 0-15, except for stenosis, where it varied between 0-11; total score ranged from 0-56. Lower score indicated better outcome.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  13. Percentage of Participants Achieving Enhanced Clinical Response

    Enhanced Clinical Response was defined as average daily stool frequency at least 65% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain score at least 35% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740.Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  14. Percentage of Participants Achieving Clinical Response

    Clinical response was defined as average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain score not worse than Baseline or average daily abdominal pain score at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  15. Percentage of Participants Achieving CDAI Response

    CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI response was defined as a reduction in CDAI scores by ≥70 from baseline of Study M13-740.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  16. Percentage of Participants Achieving Enhanced CDAI Response

    CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. Enhanced CDAI response was defined as reduction in CDAI score by ≥100 from baseline of Study M13-740.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  17. Percentage of Participants Achieving Endoscopic Response

    Endoscopic response was defined as decrease ≥ 25% SES-CD from Baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  18. Percentage of Participants Achieving IBDQ Response

    The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total Score range 32 to 224. A higher score indicated better outcome. IBDQ response was defined as an increase in IBDQ score ≥16 point from baseline of Study M13-740.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  19. Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free for At Least 90 Days and Achieve Remission

    Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5, not worse than baseline, and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI. Total score range 0 to 105. Endoscopic remission was defined as SES-CD ≤4 and at least 2- point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. SES-CD was based on endoscopic findings in 5 segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome

    Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96

  20. Change From Baseline in Fecal Calprotectin Levels

    Stool samples were collected for analysis of fecal calprotectin levels.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  21. Change From Baseline in Hs-CRP Levels

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  22. Change From Baseline in IBDQ Total Score

    The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range from 32 to 224. A higher score indicated better outcome.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

  23. Change From Baseline in SES-CD

    The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.

    Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96

07

Results

Posted Aug 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Started312947
Received at least 1 dose of study drug312947
Completed10416
Not completed212531
Withdrew: Adverse event836
Withdrew: Withdrawal by subject7210
Withdrew: Lost to follow-up103
Withdrew: Lack of efficacy4129
Withdrew: Required alternative (or prohibited) therapy031
Withdrew: Participant non-compliance141
Withdrew: Other, not specified011

Outcome measures

PrimaryPercentage of Participants Achieving Endoscopic Remission at Month 12

Endoscopic remission was based on Simplified Endoscopic Score for Crohn's disease (SES-CD). The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Remission at Month 12
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Percentage of Participants Achieving Endoscopic Remission at Month 1254.554.546.9
PrimaryPercentage of Participants Achieving Clinical Remission at Month 12

Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than Baseline and average daily abdominal pain score ≤1.0 and not worse than baseline in Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Month 12
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Percentage of Participants Achieving Clinical Remission at Month 1245.255.251.1
SecondaryPercentage of Participants Achieving Endoscopic Remission

Endoscopic remission was based on SES-CD. The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

Time frame:
Week 0 (Baseline), Months 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 025.023.132.6
Month 2453.330.854.2
Month 3650.060.058.3
Month 4870.040.056.3
Month 6050.080.080.0
Month 7255.642.953.3
Month 8490.040.071.4
Month 9657.166.776.9
SecondaryPercentage of Participants Achieving Clinical Remission

Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 035.544.840.4
Month 2438.744.844.7
Month 3645.244.842.6
Month 4841.941.442.6
Month 6041.937.942.6
Month 7241.937.940.4
Month 8441.937.942.6
Month 9641.931.042.6
SecondaryPercentage of Participants Achieving Modified Clinical Remission

Modified Clinical Remission was defined as average daily stool frequency ≤2.8 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740, among participants with stool frequency ≥4.0 or abdominal pain score ≥2.0 at Baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Modified Clinical Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 057.153.857.8
Month 1257.161.557.8
Month 2450.057.755.6
Month 3653.657.753.3
Month 4853.661.553.3
Month 6053.650.053.3
Month 7253.653.857.8
Month 8453.653.857.8
Month 9653.650.057.8
SecondaryPercentage of Participants Achieving Remission

Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 014.315.414.0
Month 1233.333.333.3
Month 2442.9038.1
Month 3666.737.547.8
Month 4862.522.246.2
Month 6050.040.061.5
Month 7255.625.040.0
Month 8475.025.066.7
Month 9657.133.370.0
SecondaryPercentage of Participants Achieving CDAI Remission

CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a pre-specified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher CDAI scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI remission was defined as CDAI score \<150.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving CDAI Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 064.558.668.1
Month 1261.362.159.6
Month 2454.844.857.4
Month 3661.341.457.4
Month 4861.337.955.3
Month 6058.137.957.4
Month 7261.341.455.3
Month 8461.341.457.4
Month 9658.137.957.4
SecondaryPercentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission

The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range: 32 to 224. A higher score indicating better outcome. IBDQ remission was defined as IBDQ score ≥170.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 053.651.759.6
Month 1256.540.072.2
Month 2458.870.070.0
Month 3690.958.379.2
Month 4883.363.690.0
Month 6066.760.089.5
Month 7266.771.493.8
Month 8454.560.092.9
Month 9677.875.093.3
SecondaryPercentage of Participants Achieving Endoscopic Improvement

Endoscopic improvement was defined as SES-CD at least 50% reduction from Baseline or endoscopic remission. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Improvement
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 057.150.065.1
Month 1281.863.668.8
Month 2473.346.270.8
Month 3690.070.070.8
Month 4890.070.075.0
Month 6010010086.7
Month 7288.971.473.3
Month 8490.060.078.6
Month 9610010084.6
SecondaryPercentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free at the Specified Timepoint in Study M14-327
Time frame:
Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free at the Specified Timepoint in Study M14-327
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Month 1278.685.761.5
Month 2464.357.153.8
Month 3657.142.953.8
Month 4850.042.946.2
Month 6042.935.738.5
Month 7242.928.630.8
Month 8442.921.430.8
Month 96000
SecondaryPercentage of Participants Achieving Remission and Normal C-Reactive Protein (CRP)

Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated: none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over the past 7 days and multiplied by a prespecified factor of 5; total score range from 0 to 105. Endoscopic remission was based on SES-CD and assessed size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum; scored 0 to 3 per segment. Sum of scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Normal CRP=high-sensitivity CRP \<5 mg/L.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission and Normal C-Reactive Protein (CRP)
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 010.715.49.3
Month 1228.630.030.0
Month 2423.1023.8
Month 3650.012.543.5
Month 4850.012.545.5
Month 6050.025.053.8
Month 7250.025.035.7
Month 8462.525.050.0
Month 9642.933.350.0
SecondaryPercentage of Participants in Remission at Week 0 Who Maintained Remission

Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

Time frame:
Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants in Remission at Week 0 Who Maintained Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Month 1210025.080.0
Month 2466.7—100
Month 36100100100
Month 48100100100
Month 60100100100
Month 7210010050.0
Month 84100100100
Month 9610050.0100
SecondaryPercentage of Participants in Endoscopic Remission at Week 0 Who Maintained Endoscopic Remission

Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.

Time frame:
Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants in Endoscopic Remission at Week 0 Who Maintained Endoscopic Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Month 1210066.772.7
Month 2410075.080.0
Month 3610010080.0
Month 4810010060.0
Month 60100100100
Month 7210066.775.0
Month 8410010075.0
Month 96100100100
SecondaryPercentage of Participants Achieving Response

Response = clinical and endoscopic response. Clinical response was average daily stool frequency at least 30% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain based on CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over past 7 days and multiplied by prespecified factor of 5; total score range from 0-105. Endoscopic response was decrease ≥25% SES-CD from baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, rectum), scored 0 to 3 per each segment. Sum of the scores for each endoscopic variable ranged from 0-15, except for stenosis, where it varied between 0-11; total score ranged from 0-56. Lower score indicated better outcome.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 067.953.872.1
Month 1285.771.473.3
Month 2485.760.085.7
Month 3610062.573.9
Month 4887.566.776.9
Month 6087.580.084.6
Month 7288.975.086.7
Month 8487.575.075.0
Month 9610010080.0
SecondaryPercentage of Participants Achieving Enhanced Clinical Response

Enhanced Clinical Response was defined as average daily stool frequency at least 65% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain score at least 35% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740.Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Enhanced Clinical Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 077.472.480.9
Month 1274.269.080.9
Month 2467.769.080.9
Month 3671.065.583.0
Month 4871.069.083.0
Month 6071.062.178.7
Month 7271.065.580.9
Month 8471.065.578.7
Month 9667.762.178.7
SecondaryPercentage of Participants Achieving Clinical Response

Clinical response was defined as average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain score not worse than Baseline or average daily abdominal pain score at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 080.675.983.0
Month 1274.275.985.1
Month 2471.075.985.1
Month 3671.072.485.1
Month 4871.079.385.1
Month 6071.069.080.9
Month 7271.072.483.0
Month 8471.072.480.9
Month 9667.772.480.9
SecondaryPercentage of Participants Achieving CDAI Response

CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI response was defined as a reduction in CDAI scores by ≥70 from baseline of Study M13-740.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving CDAI Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 083.975.978.7
Month 1277.482.878.7
Month 2477.486.276.6
Month 3677.479.374.5
Month 4877.482.868.1
Month 6074.269.074.5
Month 7277.475.972.3
Month 8477.475.972.3
Month 9677.472.474.5
SecondaryPercentage of Participants Achieving Enhanced CDAI Response

CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. Enhanced CDAI response was defined as reduction in CDAI score by ≥100 from baseline of Study M13-740.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Enhanced CDAI Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 077.469.076.6
Month 1274.272.472.3
Month 2471.075.974.5
Month 3671.069.070.2
Month 4871.069.066.0
Month 6067.762.168.1
Month 7274.269.070.2
Month 8471.069.070.2
Month 9674.265.570.2
SecondaryPercentage of Participants Achieving Endoscopic Response

Endoscopic response was defined as decrease ≥ 25% SES-CD from Baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 085.761.581.4
Month 1290.981.875.0
Month 2493.361.587.5
Month 3690.080.079.2
Month 4810080.081.3
Month 6010010086.7
Month 7288.985.786.7
Month 8410080.085.7
Month 9610010084.6
SecondaryPercentage of Participants Achieving IBDQ Response

The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total Score range 32 to 224. A higher score indicated better outcome. IBDQ response was defined as an increase in IBDQ score ≥16 point from baseline of Study M13-740.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IBDQ Response
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 085.779.378.7
Month 1287.068.072.2
Month 2482.480.086.7
Month 3610091.783.3
Month 4810090.980.0
Month 6010090.078.9
Month 7210085.781.3
Month 8481.880.085.7
Month 9688.910093.3
SecondaryPercentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free for At Least 90 Days and Achieve Remission

Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5, not worse than baseline, and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI. Total score range 0 to 105. Endoscopic remission was defined as SES-CD ≤4 and at least 2- point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. SES-CD was based on endoscopic findings in 5 segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome

Time frame:
Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free for At Least 90 Days and Achieve Remission
percentage of participantsUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Month 1236.433.360.0
Month 2442.9033.3
Month 3633.340.066.7
Month 4850.040.0100
Month 6040.050.0100
Month 7240.050.075.0
Month 8475.050.0100
Month 9640.0066.7
SecondaryChange From Baseline in Fecal Calprotectin Levels

Stool samples were collected for analysis of fecal calprotectin levels.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Mean · micrograms (μg)/grams (g)
Change From Baseline in Fecal Calprotectin Levels
micrograms (μg)/grams (g)Upadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 0-786.5 ± 2286.47-1623.9 ± 2811.99-1050.8 ± 1654.69
Month 12-1237.7 ± 2441.85-1323.4 ± 2391.92-993.7 ± 1249.74
Month 24-1633.2 ± 2682.72-1381.7 ± 2595.10-1791.9 ± 2273.29
Month 36-1748.6 ± 1107.85-652.8 ± 986.68-1477.7 ± 1766.91
Month 48-1271.6 ± 2062.18-1024.4 ± 4547.76-1466.6 ± 1374.09
Month 60-2126.4 ± 2309.74-1225.6 ± 720.88-1485.2 ± 1481.70
Month 72-1120.0 ± 1812.65-1501.2 ± 4874.08-1004.6 ± 884.68
Month 84-1338.0 ± 1161.16-1451.3 ± 6321.77-2121.4 ± 1871.52
Month 96-994.8 ± 1281.72-1049.5 ± 757.31-1889.4 ± 1490.62
SecondaryChange From Baseline in Hs-CRP Levels
Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Mean · mg/L
Change From Baseline in Hs-CRP Levels
mg/LUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 0-12.377 ± 26.6146-3.954 ± 37.5299-11.310 ± 19.6428
Month 12-7.901 ± 36.4956-9.843 ± 22.1230-10.757 ± 18.3601
Month 24-14.663 ± 25.2412-11.406 ± 20.5222-9.833 ± 20.7197
Month 36-17.782 ± 32.0214-13.118 ± 24.1039-13.069 ± 21.3781
Month 48-19.629 ± 29.3289-15.104 ± 23.4962-11.909 ± 25.4634
Month 60-18.125 ± 29.9039-9.671 ± 17.7615-13.324 ± 27.3104
Month 72-18.215 ± 28.5997-18.624 ± 26.3939-14.891 ± 25.7492
Month 84-20.361 ± 26.9004-26.278 ± 28.2083-14.704 ± 25.8847
Month 96-20.380 ± 31.6487-24.517 ± 37.5441-8.200 ± 34.1356
SecondaryChange From Baseline in IBDQ Total Score

The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range from 32 to 224. A higher score indicated better outcome.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Mean · score on a scale
Change From Baseline in IBDQ Total Score
score on a scaleUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 050.8148 ± 32.582548.9310 ± 39.672750.7367 ± 45.9608
Month 1259.4545 ± 29.380542.5200 ± 36.950653.2254 ± 46.4930
Month 2449.5294 ± 31.688261.2000 ± 40.698662.8927 ± 41.7239
Month 3669.3636 ± 24.585765.6667 ± 39.102067.6087 ± 40.4663
Month 4870.3333 ± 23.933069.1818 ± 42.890169.1053 ± 41.6958
Month 6068.0833 ± 27.661872.4636 ± 42.907362.6111 ± 42.8405
Month 7268.4722 ± 30.259674.7922 ± 49.459258.2667 ± 34.6543
Month 8468.8182 ± 36.561889.4000 ± 53.397659.1429 ± 44.9613
Month 9668.2222 ± 32.337277.2500 ± 45.712063.4667 ± 41.3087
SecondaryChange From Baseline in SES-CD

The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.

Time frame:
Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Mean · score on a scale
Change From Baseline in SES-CD
score on a scaleUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
Week 0-10.0 ± 8.15-6.8 ± 10.33-8.9 ± 7.81
Month 12-14.0 ± 8.63-8.4 ± 11.02-9.0 ± 9.59
Month 24-14.9 ± 9.96-6.4 ± 12.29-9.3 ± 7.06
Month 36-17.3 ± 9.67-8.7 ± 12.18-11.8 ± 9.75
Month 48-18.2 ± 10.30-9.5 ± 9.64-11.6 ± 9.37
Month 60-19.4 ± 8.68-15.6 ± 9.15-12.8 ± 9.15
Month 72-16.4 ± 10.32-10.4 ± 8.83-11.5 ± 10.03
Month 84-19.2 ± 9.33-8.2 ± 10.26-12.4 ± 9.87
Month 96-19.0 ± 8.72-13.7 ± 9.87-11.1 ± 9.24

Adverse events

Collected over From first dose of study drug through 96 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Upadacitinib 30 mg0/31 (0%)9/31 (29%)31/31 (100%)
Upadacitinib 15 mg, Then 30 mg0/29 (0%)7/29 (24.1%)27/29 (93.1%)
Upadacitinib 15 mg1/47 (2.1%)15/47 (31.9%)41/47 (87.2%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
CROHN'S DISEASEGASTROINTESTINAL DISORDERS4/314/293/47
ANAL ABSCESSINFECTIONS AND INFESTATIONS3/310/290/47
ILEUSGASTROINTESTINAL DISORDERS0/311/290/47
LARGE INTESTINE PERFORATIONGASTROINTESTINAL DISORDERS0/311/290/47
SMALL INTESTINAL OBSTRUCTIONGASTROINTESTINAL DISORDERS1/311/290/47
CHOLELITHIASISHEPATOBILIARY DISORDERS0/311/290/47
DRUG-INDUCED LIVER INJURYHEPATOBILIARY DISORDERS0/311/290/47
ABDOMINAL ABSCESSINFECTIONS AND INFESTATIONS1/311/290/47
GASTROENTERITIS VIRALINFECTIONS AND INFESTATIONS0/311/291/47
TYPE 2 DIABETES MELLITUSMETABOLISM AND NUTRITION DISORDERS0/311/290/47
Most frequent other events
Showing 10 of 104
Most frequent other events
EventUpadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mg
CROHN'S DISEASEGASTROINTESTINAL DISORDERS9/3113/299/47
COVID-19INFECTIONS AND INFESTATIONS7/317/2916/47
NASOPHARYNGITISINFECTIONS AND INFESTATIONS10/315/2910/47
UPPER RESPIRATORY TRACT INFECTIONINFECTIONS AND INFESTATIONS8/316/298/47
ARTHRALGIAMUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS7/317/297/47
FATIGUEGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS7/316/299/47
BLOOD CREATINE PHOSPHOKINASE INCREASEDINVESTIGATIONS7/315/298/47
ACNESKIN AND SUBCUTANEOUS TISSUE DISORDERS7/311/293/47
HYPERTENSIONVASCULAR DISORDERS7/312/294/47
URINARY TRACT INFECTIONINFECTIONS AND INFESTATIONS5/316/299/47

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants who enrolled into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Upadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mgTotal
Mean38.4 ± 13.5541.0 ± 14.4240.8 ± 11.6540.2 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)Upadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mgTotal
Female17142556
Male14152251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Upadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mgTotal
Hispanic or Latino2349
Not Hispanic or Latino29264398
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Upadacitinib 30 mgUpadacitinib 15 mg, Then 30 mgUpadacitinib 15 mgTotal
American Indian or Alaska Native0000
Asian1214
Native Hawaiian or Other Pacific Islander0000
Black or African American3137
White27264396
More than one race0000
Unknown or Not Reported0000
08

Study locations

61 sites
  • UC San Diego Health System /ID# 150041
    La Jolla, California 92037, United States
  • Univ California, San Francisco /ID# 149987
    San Francisco, California 94143-2204, United States
  • Duplicate_University of Florida - Archer /ID# 150033
    Gainesville, Florida 32610, United States
  • The Ctr for Gastro Disorders /ID# 150012
    Hollywood, Florida 33021, United States
  • Nature Coast Clinical Research - Inverness /ID# 149975
    Inverness, Florida 34452-4717, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 149870
    Macon, Georgia 31201, United States
  • GI Specialists of GA, PC /ID# 150015
    Marietta, Georgia 30060, United States
  • Cotton O'Neil Clinical Research Center, Digestive Health /ID# 149900
    Topeka, Kansas 66606, United States
  • Duplicate_University of Louisville /ID# 149884
    Louisville, Kentucky 40202, United States
  • Investigative Clinical Research /ID# 149886
    Annapolis, Maryland 21401, United States
  • Charm City Research Group /ID# 150040
    Towson, Maryland 21204, United States
  • Clin Res Inst of Michigan, LLC /ID# 150008
    Chesterfield, Michigan 48047, United States
  • Mayo Clinic - Rochester /ID# 149894
    Rochester, Minnesota 55905-0001, United States
  • Kansas City Research Institute /ID# 149888
    Kansas City, Missouri 64131, United States
  • Washington University-School of Medicine /ID# 149899
    St Louis, Missouri 63110, United States
  • NYU Langone Long Island Clinical Research Associates /ID# 149976
    Lake Success, New York 11042, United States
  • Weill Cornell Medicine/NYP /ID# 149895
    New York, New York 10021-4872, United States
  • Univ NC Chapel Hill /ID# 149982
    Chapel Hill, North Carolina 27514-4220, United States
  • University Of Cincinnati Medical Center /ID# 149977
    Cincinnati, Ohio 45219, United States
  • Options Health Research, LLC /ID# 150010
    Tulsa, Oklahoma 74104, United States
  • Texas Digestive Disease Consultants - Southlake /ID# 149869
    Southlake, Texas 76092, United States
  • Texas Digestive Disease Consultants - Southlake /ID# 149989
    Southlake, Texas 76092, United States
  • Aspen Clinical Research /ID# 150020
    Orem, Utah 84058, United States
  • University of Virginia /ID# 149881
    Charlottesville, Virginia 22908, United States
  • Virginia Mason Hospital & Medical Center /ID# 150042
    Seattle, Washington 98101, United States
  • University of Washington /ID# 149988
    Seattle, Washington 98109, United States
  • Wisconsin Center for Advanced Research /ID# 149863
    Milwaukee, Wisconsin 53215, United States
  • Duplicate_CHU de Liege /ID# 149912
    Liège, Liege 4000, Belgium
  • University of Alberta Hospital /ID# 149873
    Edmonton, Alberta T6G 2B7, Canada
  • University of British Columbia (UBC) - Gordon and Leslie Diamond Health Care Ce /ID# 149876
    Vancouver, British Columbia V5Z 1M9, Canada
  • Duplicate_(G.I.R.I.) GI Research Institute Foundation /ID# 149878
    Vancouver, British Columbia V6Z 2K5, Canada
  • Toronto Digestive Disease Associates /ID# 149877
    Vaughan, Ontario L4L 4Y7, Canada
  • Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 149871
    Montreal, Quebec H4A 3J1, Canada
  • Hepato-Gastroenterologie HK, s.r.o. /ID# 149882
    Hradec Králové, Hradec Kralove 500 12, Czechia
  • Kobenhavns Universitet - Hvidovre Hospital (HH) /ID# 149890
    Hvidovre, Capital Region 2650, Denmark
  • Duplicate_Aarhus University Hospital /ID# 149919
    Aarhus N, Central Jutland 8200, Denmark
  • Duplicate_CHRU Nancy - Hopitaux de Brabois /ID# 149896
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • CHRU Lille - Hopital Claude Huriez /ID# 149897
    Lille, Nord 59037, France
  • Duplicate_CHU Amiens-Picardie Site Sud /ID# 149921
    Amiens, Somme 80054, France
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 149936
    Kiel, Schleswig-Holstein 24105, Germany
  • DRK Kliniken Berlin Westend /ID# 149905
    Berlin, 14050, Germany
  • Medizinisches Versorgungszentrum Portal 10 /ID# 149930
    Münster, 48155, Germany
  • Magyar Elhizastudomanyi Kozpont Kft. /ID# 149907
    Budapest, 1124, Hungary
  • Yitzhak Shamir Medical Center /ID# 149943
    Ẕerifin, Central District 70300, Israel
  • The Chaim Sheba Medical Center /ID# 149945
    Ramat Gan, Tel Aviv 5265601, Israel
  • Rabin Medical Center. /ID# 149942
    Petah Tikva, 4941492, Israel
  • University of Catanzaro /ID# 149927
    Catanzaro, Calabria 88100, Italy
  • Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 149958
    Bologna, Emilia-Romagna 40138, Italy
  • Amsterdam UMC, locatie AMC /ID# 149932
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Universitair Medisch Centrum Utrecht /ID# 149933
    Utrecht, Utrecht 3584 CX, Netherlands
  • Dunedin Hospital /ID# 149964
    Otago, Otago 9016, New Zealand
  • Lovisenberg Diakonale Sykehus /ID# 149967
    Oslo, Oslo 0440, Norway
  • Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 149978
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Santa Sp. z o.o. Santa Familia Centrum Badan, Profilaktyki i Leczenia /ID# 149979
    Lodz, Łódź Voivodeship 90-302, Poland
  • Cabinet Particular Policlinic Algomed /ID# 149993
    Timișoara, 300002, Romania
  • Duplicate_KM Management, spol. s.r.o. /ID# 149949
    Nitra, Nitra Region 949 01, Slovakia
  • Gastro I., s.r.o. /ID# 149948
    Prešov, Presov 080 01, Slovakia
  • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 149996
    Ferrol, A Coruna 15405, Spain
  • Hospital Universitario La Paz /ID# 149997
    Madrid, Madrid 28046, Spain
  • Duplicate_Manchester University NHS Foundation Trust /ID# 150006
    Manchester, Manchester M13 9WL, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust /ID# 149963
    Oxford, Oxfordshire OX3 9DU, United Kingdom
09

References and documents

Publications

  • D'Haens G, Panes J, Louis E, Lacerda A, Zhou Q, Liu J, Loftus EV Jr. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2337-2346.e3. doi: 10.1016/j.cgh.2021.12.030. Epub 2021 Dec 27. PubMed 34968730 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jul 2025, 110 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 110 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
May 25, 2016
StartActual
May 18, 2016
Primary completionActual
Jul 18, 2025
CompletionActual
Jul 18, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02782663
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 25, 2016
Start date
May 18, 2016
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion